These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 12831788)

  • 21. Current drug metabolism.
    Kerns EH
    Curr Drug Metab; 2008 Nov; 9(9):845-6. PubMed ID: 18991579
    [No Abstract]   [Full Text] [Related]  

  • 22. The role of the intestine in drug metabolism and pharmacokinetics: an industry perspective.
    Fisher MB; Labissiere G
    Curr Drug Metab; 2007 Oct; 8(7):694-9. PubMed ID: 17979657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimum acceptable requirements for introduction and marketing of drugs.
    Lasagna L
    Drugs; 1974; 7(6):409-13. PubMed ID: 4422210
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmaceutical drugs-the good and the not so good: together, we can make it better.
    Campbell AW
    Altern Ther Health Med; 2014; 20(1):9-11. PubMed ID: 24445351
    [No Abstract]   [Full Text] [Related]  

  • 25. The role of metabolites in bioequivalence.
    Midha KK; Rawson MJ; Hubbard JW
    Pharm Res; 2004 Aug; 21(8):1331-44. PubMed ID: 15359567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unique/major human metabolites: why, how, and when to test for safety in animals.
    Luffer-Atlas D
    Drug Metab Rev; 2008; 40(3):447-63. PubMed ID: 18642142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How Much Nonclinical Safety Data Are Required for a Clinical Study in Ophthalmology?
    Novack GD; Moyer ED
    J Ocul Pharmacol Ther; 2016; 32(1):5-10. PubMed ID: 26539734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The do's and don'ts of preclinical development.
    Graffeo A
    Biotechnology (N Y); 1994 Sep; 12(9):865-9. PubMed ID: 7765226
    [No Abstract]   [Full Text] [Related]  

  • 29. Drugs in control samples in nonclinical safety studies: a reconsideration.
    Zimmer D
    Bioanalysis; 2016 May; 8(10):1003-7. PubMed ID: 27080047
    [No Abstract]   [Full Text] [Related]  

  • 30. Drug metabolites in safety testing.
    Baillie TA; Cayen MN; Fouda H; Gerson RJ; Green JD; Grossman SJ; Klunk LJ; LeBlanc B; Perkins DG; Shipley LA
    Toxicol Appl Pharmacol; 2002 Aug; 182(3):188-96. PubMed ID: 12229863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microdosing for reduction of the time and resources for drug development.
    Sudo K
    Drug Metab Pharmacokinet; 2007 Oct; 22(5):327. PubMed ID: 17965515
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug safety: experimental programs.
    Zbinden G
    Science; 1969 May; 164(3880):643-7. PubMed ID: 4888107
    [No Abstract]   [Full Text] [Related]  

  • 33. Requirements for a lead compound to become a clinical candidate.
    Hefti FF
    BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S7. PubMed ID: 19091004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significance of metabolic patterns in teratogenic testing for food safety.
    Khera KS
    Clin Toxicol; 1976; 9(5):773-90. PubMed ID: 826367
    [No Abstract]   [Full Text] [Related]  

  • 35. Application of pharmacokinetic data to clinical trials during the IND/NDA process.
    Harter JG
    J Clin Pharmacol; 1976 Oct; 16(10 Pt 2):560-4. PubMed ID: 977796
    [No Abstract]   [Full Text] [Related]  

  • 36. Natural products research: perspectives from a major pharmaceutical company.
    Borris RP
    J Ethnopharmacol; 1996 Apr; 51(1-3):29-38. PubMed ID: 9213624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A perspective on US drug reimportation.
    Choudhry NK; Detsky AS
    JAMA; 2005 Jan; 293(3):358-62. PubMed ID: 15657329
    [No Abstract]   [Full Text] [Related]  

  • 38. Metabolite Identification in the Preclinical and Clinical Phase of Drug Development.
    Wu Y; Pan L; Chen Z; Zheng Y; Diao X; Zhong D
    Curr Drug Metab; 2021; 22(11):838-857. PubMed ID: 34620061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health.
    Gostin LO
    JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642
    [No Abstract]   [Full Text] [Related]  

  • 40. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism.
    Baillie TA
    Chem Res Toxicol; 2008 Jan; 21(1):129-37. PubMed ID: 18052111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.